• About Us
    • About MS Australia
    • Our People
    • Partnerships
    • Reports and Financials
  • For People with MS
    • What is MS?
      • How is MS diagnosed?
      • Types of MS
      • MS Treatments
    • MS Symptoms
    • Clinical Trials for MS
      • PLATYPUS
      • STOP-MS
      • FIRMS-EBV
      • Other MS Clinical Trials
    • COVID-19 and MS
    • Crisis Toolkit
    • Employment
    • Family, friends and other carers
    • Health and Wellbeing
    • MS Clinics
    • NMOSD and MOGAD
    • Participate in MS Research
    • Support and Services
  • FOR RESEARCHERS
    • Funding Opportunities
    • Online Grant Portal
    • MS Research Resource Portal
    • Grant Documents and Templates
    • Research We Fund
  • Research
    • Research We Fund
    • Research Strategy and Governance
    • Australian MS Clinical Trials Platform
    • National Collaborations
      • AHSCT
      • ANZgene
      • Ausimmune Study
      • Australian MS Longitudinal Study
      • EBV in MS
      • InforMS
      • MS Brain Bank
      • Proteomics of MS
      • Vitamin D MS Prevention Trial – PrevANZ
    • Global Collaborations
      • International Progressive MS Alliance
      • Kiss Goodbye to MS
      • The International MS Genetics Consortium
      • MS Brain Health
      • MS International Federation (MSIF)
    • Participate in MS Research
    • MS Glossary
  • Advocacy
    • Aged Care
    • Alliances
    • Budgets and Elections
    • Carer Strategy
    • Consumer Engagement Roadmap
    • Lived Experience Expert Panel
    • NDIS
    • NDIS Pricing
    • MS Nurses
    • Parliamentary Friends of MS
    • Submissions
  • Get Involved
    • Donate
    • Corporate involvement
    • Events
    • MS Australia Awards 2025
    • Participate in MS research
    • Volunteers
  • About Us
    • About MS Australia
    • Our People
    • Partnerships
    • Reports and Financials
  • For People with MS
    • What is MS?
      • How is MS diagnosed?
      • Types of MS
      • MS Treatments
    • MS Symptoms
    • Clinical Trials for MS
      • PLATYPUS
      • STOP-MS
      • FIRMS-EBV
      • Other MS Clinical Trials
    • COVID-19 and MS
    • Crisis Toolkit
    • Employment
    • Family, friends and other carers
    • Health and Wellbeing
    • MS Clinics
    • NMOSD and MOGAD
    • Participate in MS Research
    • Support and Services
  • FOR RESEARCHERS
    • Funding Opportunities
    • Online Grant Portal
    • MS Research Resource Portal
    • Grant Documents and Templates
    • Research We Fund
  • Research
    • Research We Fund
    • Research Strategy and Governance
    • Australian MS Clinical Trials Platform
    • National Collaborations
      • AHSCT
      • ANZgene
      • Ausimmune Study
      • Australian MS Longitudinal Study
      • EBV in MS
      • InforMS
      • MS Brain Bank
      • Proteomics of MS
      • Vitamin D MS Prevention Trial – PrevANZ
    • Global Collaborations
      • International Progressive MS Alliance
      • Kiss Goodbye to MS
      • The International MS Genetics Consortium
      • MS Brain Health
      • MS International Federation (MSIF)
    • Participate in MS Research
    • MS Glossary
  • Advocacy
    • Aged Care
    • Alliances
    • Budgets and Elections
    • Carer Strategy
    • Consumer Engagement Roadmap
    • Lived Experience Expert Panel
    • NDIS
    • NDIS Pricing
    • MS Nurses
    • Parliamentary Friends of MS
    • Submissions
  • Get Involved
    • Donate
    • Corporate involvement
    • Events
    • MS Australia Awards 2025
    • Participate in MS research
    • Volunteers
NEWS
RESOURCES
PODCAST
  • NEWS
  • RESOURCES
  • PODCAST
  • VIDEOS
  • CONTACT
Donate
Subscribe
Search
  • About Us
    • About MS Australia
    • Our People
    • Partnerships
    • Reports and Financials
  • For People with MS
    • What is MS?
      • How is MS diagnosed?
      • Types of MS
      • MS Treatments
    • MS Symptoms
    • Clinical Trials for MS
      • PLATYPUS
      • STOP-MS
      • FIRMS-EBV
      • Other MS Clinical Trials
    • COVID-19 and MS
    • Crisis Toolkit
    • Employment
    • Family, friends and other carers
    • Health and Wellbeing
    • MS Clinics
    • NMOSD and MOGAD
    • Participate in MS Research
    • Support and Services
  • FOR RESEARCHERS
    • Funding Opportunities
    • Online Grant Portal
    • MS Research Resource Portal
    • Grant Documents and Templates
    • Research We Fund
  • Research
    • Research We Fund
    • Research Strategy and Governance
    • Australian MS Clinical Trials Platform
    • National Collaborations
      • AHSCT
      • ANZgene
      • Ausimmune Study
      • Australian MS Longitudinal Study
      • EBV in MS
      • InforMS
      • MS Brain Bank
      • Proteomics of MS
      • Vitamin D MS Prevention Trial – PrevANZ
    • Global Collaborations
      • International Progressive MS Alliance
      • Kiss Goodbye to MS
      • The International MS Genetics Consortium
      • MS Brain Health
      • MS International Federation (MSIF)
    • Participate in MS Research
    • MS Glossary
  • Advocacy
    • Aged Care
    • Alliances
    • Budgets and Elections
    • Carer Strategy
    • Consumer Engagement Roadmap
    • Lived Experience Expert Panel
    • NDIS
    • NDIS Pricing
    • MS Nurses
    • Parliamentary Friends of MS
    • Submissions
  • Get Involved
    • Donate
    • Corporate involvement
    • Events
    • MS Australia Awards 2025
    • Participate in MS research
    • Volunteers
  • About Us
    • About MS Australia
    • Our People
    • Partnerships
    • Reports and Financials
  • For People with MS
    • What is MS?
      • How is MS diagnosed?
      • Types of MS
      • MS Treatments
    • MS Symptoms
    • Clinical Trials for MS
      • PLATYPUS
      • STOP-MS
      • FIRMS-EBV
      • Other MS Clinical Trials
    • COVID-19 and MS
    • Crisis Toolkit
    • Employment
    • Family, friends and other carers
    • Health and Wellbeing
    • MS Clinics
    • NMOSD and MOGAD
    • Participate in MS Research
    • Support and Services
  • FOR RESEARCHERS
    • Funding Opportunities
    • Online Grant Portal
    • MS Research Resource Portal
    • Grant Documents and Templates
    • Research We Fund
  • Research
    • Research We Fund
    • Research Strategy and Governance
    • Australian MS Clinical Trials Platform
    • National Collaborations
      • AHSCT
      • ANZgene
      • Ausimmune Study
      • Australian MS Longitudinal Study
      • EBV in MS
      • InforMS
      • MS Brain Bank
      • Proteomics of MS
      • Vitamin D MS Prevention Trial – PrevANZ
    • Global Collaborations
      • International Progressive MS Alliance
      • Kiss Goodbye to MS
      • The International MS Genetics Consortium
      • MS Brain Health
      • MS International Federation (MSIF)
    • Participate in MS Research
    • MS Glossary
  • Advocacy
    • Aged Care
    • Alliances
    • Budgets and Elections
    • Carer Strategy
    • Consumer Engagement Roadmap
    • Lived Experience Expert Panel
    • NDIS
    • NDIS Pricing
    • MS Nurses
    • Parliamentary Friends of MS
    • Submissions
  • Get Involved
    • Donate
    • Corporate involvement
    • Events
    • MS Australia Awards 2025
    • Participate in MS research
    • Volunteers
Initial phase 3 results for tolebrutinib show a reduction in disability accumulation in people with non-relapsing secondary progressive MS 5 September 2024
MS News MS Trials
Initial phase 3 results for tolebrutinib show a reduction in disability accumulation in people with non-relapsing secondary progressive MS
Empowering Nurse Practitioners to Improve Access to MS Care 5 September 2024
MS News MS Trials
Empowering Nurse Practitioners to Improve Access to MS Care
Adjusting workplace factors may improve employment outcomes for people with MS 28 August 2024
MS News MS Trials
Adjusting workplace factors may improve employment outcomes for people with MS
Australian study finds lower doses of rituximab may be effective in treating NMOSD 28 August 2024
MS News MS Trials
Australian study finds lower doses of rituximab may be effective in treating NMOSD
Promising New Treatment in the PIPEline for Remyelination in MS 28 August 2024
MS News MS Trials
Promising New Treatment in the PIPEline for Remyelination in MS
MS Neurologist and EBV researcher recognised in King’s Birthday Honours 31 July 2024
MS Brainbank MS News MS Trials
MS Neurologist and EBV researcher recognised in King’s Birthday Honours
Improving sleep quality in Australians with MS by managing comorbidities 31 July 2024
MS Brainbank MS News MS Trials
Improving sleep quality in Australians with MS by managing comorbidities
Exploring Repetitive Transcranial Magnetic Stimulation (rTMS) as a Potential Treatment for Multiple Sclerosis 26 June 2024
MS News MS Trials
Exploring Repetitive Transcranial Magnetic Stimulation (rTMS) as a Potential Treatment for Multiple Sclerosis
Enlargement of a discrete brain region is providing clues on nerve damage in relapsing remitting MS 26 June 2024
MS Brainbank MS News MS Trials
Enlargement of a discrete brain region is providing clues on nerve damage in relapsing remitting MS
COVID-19: What did it do to quality of life in MS? 26 June 2024
MS Brainbank MS Trials
COVID-19: What did it do to quality of life in MS?
Load More
MS Australia
registered charity

1300 010 158

info@msaustralia.org.au

Head Office

Suite 3.01, 18 Flour Mill Way
Summer Hill NSW 2130

Participate in MS Research

  • MS Clinical Trials
  • MS Australia Brain Bank
  • Australian MS Longitudinal Study
Facebook-f X-twitter Linkedin-in Youtube Instagram Spotify Paper-plane

Quick links

  • What is MS?
  • How is MS diagnosed?
  • COVID-19 and MS
  • Research funding opportunities
  • Research we fund
  • Media enquiries
  • Contact us
© 2026 Multiple Sclerosis Australia | ABN: 51 008 515 508 │Privacy Policy | Whistleblower Policy | Complaints Policy | Terms and Conditions
© 2024 Multiple Sclerosis Australia
ABN: 51 008 515 508
Privacy Policy | Whistleblower Policy
Complaints Policy | Terms and Conditions
SUBSCRIBE
DONATE
CONTACT

Newsletter subscription

  • This field is for validation purposes and should be left unchanged.

Initial phase 3 results for tolebrutinib show a reduction in disability accumulation in people with non-relapsing secondary progressive MS